Alcohol Dependence Clinical Trial
— QICAOfficial title:
Qi Gong as a Method of Craving Reduction in Severe Addict Patients
Craving arises in response to an affective tone that is associated with perceptual
representations of a sensory object, rather than directly in response to the object.
The investigators presume that qi gong functions to decouple pleasant and unpleasant
experience from habitual reactions by removing the affective bias that fuels such emotional
reactivity. Qi gong training may specifically target the associated learning process with an
emphasis on the critical link between affect and craving in an addictive loop.
Status | Recruiting |
Enrollment | 186 |
Est. completion date | December 2020 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria - Meets DSM 5 criteria for alcohol use disorder and other substance use disorders - Alcohol is one of the major abused substances if using multiple substances - Severity of the disorder defines by the necessity of a complex withdrawal hospitalization. - Used alcohol in the 3 weeks before hospitalization - Seeks addiction treatment - Patient willing to adhere to the study protocol (e.g. attend all visits and follow-ups in the next 3 months). - Age = 18 - Negative pregnancy test (ßHCG) for women of child bearing potential - Signed informed consent - Affiliation to the French health insurance (recipient or assign) - Oral and written comprehension of the french langage Non-inclusion criteria - Pose a current suicidal risk including active suicidal ideation and suicide attempt in the past 30 days - Non stabilized severe psychiatric comorbidities such as bipolar disorder, schizophrenia, … (at the investigator's discretion) - Pregnant or breastfeeding women - Decompensated cirrhosis, liver encephalopathy, neurological complications, severe cognitive impairment and any other severe somatic comorbidity (at the investigator's discretion) - Currently participated in other interventional clinical study - Individuals placed under guardianship - Patient deprived of freedom |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Saint ELOI | Montpellier | |
France | Hôpital L'ARCHET | Nice | |
France | Groupe Hospitalier Pitié Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variation of craving intensity | Variation of craving intensity on a Vvisual aAnalogic sScale (VAS) between baseline and the end of the treatment. The intensity is measured by "not at all" (score of 0) and "craving as bad as it could be" or "the most I've ever felt " (maximum score of 10), self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents his craving intensity. The score is determined by measuring the distance on the 10-cm line between the "no craving" anchor and the patient's mark. |
Change in VAS from baseline to 9 weeks treatment | |
Secondary | Evolution over time of craving intensity | Craving intensity measured with 14-items Obsessive Compulsive Drinking Scale (OCDS). OCDS score is the sum of two subscales scores. Obsessive Subscale is calculated from items 1 to 6, maximal subscore is 20 (worse outcome). Compulsive subscale is calculated from items 7 to 14. |
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Difference in treatment retention | Difference in treatment retention (permanence rate) | 3 weeks and 9 weeks post-baseline | |
Secondary | Evolution over time of total alcohol consumption | Alcohol consumption assessed with Time Line Follow Back (TLFB) | 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Evoluation over time of anxiety | Anxiety questions sum score of Hospital Anxiety and Depression scale (HAD scale). Seven questions are related to anxiety (total A). Anxiety is measured by the sum score questions 1 , 4, 6 , 8, 10 , 12, 14. . Non : Total A = 1,3,5,7,9,11,13 The maximum score being equal to 21 : 0-7: normal; 8-10 bordeline abnormal (borderline case); 11-21 : abnormal (case) |
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Evolution over time of depression | Depression questions sum score of Hospital Anxiety and Depression scale (HAD scale). Seven questions are related to the depressive dimension (total D). Depression is measured by the sum score questions 2, 3, 5 , 7, 9 , 11, 13 Non: Total D : 2,4,6,8,10,12,14. The maximum score being equal to 21 : 0-7: normal; 8-10: bordeline abnormal (borderline case); 11-21: abnormal (case) |
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Psycological qualitative evaluation | Qualitative evaluation assessed with clinical notes | 1 day, 2 days, 3 days, 4 days, 5 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks and 9 weeks post-baseline | |
Secondary | Evolution over time of total alcohol consumption measured by GGT biomarker | GGT Gamma glutamyl transpeptidase levels in UI/I | at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Evolution over time of total alcohol consumption measured by Carbohydrate-Deficient Transferrin (CDT) marker | CDT levels in % | at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline | |
Secondary | Evolution over time of total alcohol consumption measured by Mean Globular Volume (MGV) marker | MGV levels in fL | at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |